Ivan Milas
Associate Professor at the School of Medicine, Catholic University of Croatia. He graduated and received his PhD from the School of Medicine, University of Zagreb, where he defended his doctoral dissertation in 2005 on the topic of the prognostic significance of the Cox-2 protein in patients with breast cancer. He passed the specialist examination in general surgery in 1999, and in 2006 in plastic, aesthetic and reconstructive surgery, and in 2010 in oncological surgery. At the University Hospital for Tumors, Sestre milosrdnice University Hospital Center, he worked as the head of the polyclinic and as the head of the center for genetic and oncological counseling. From 2019 to 2022, he worked as the acting head of the Tumor Clinic. KBCSM. Since January 2020, he has been the editor-in-chief of the journal Libri Oncologici. Since 2025, he has been the head of the Surgery course at the School of Medicine, Catholic University of Croatia.
SCIENTIFIC-RESEARCH INTERESTS:
Oncology, molecular biology of tumors, new methods in oncological and reconstructive surgery
COURSES:
Surgery
Prevention, diagnosis and treatment of malignant tumors
Surgery, traumatology and orthopedics
PROJECTS:
Biomarkers as a predictor of brain metastases. At MD Anderson Cancer Center, Houston, USA. Associate (2001-2002)
MZT RH: Biomarkers of cell genome damage in ecogenetic research. Consultant (2002-2006)
ICTGEN: Information and communication technology for generic and energy-efficient communication solutions with application in e-/m-health. Associate (2007-2013).
BICRO: Medical imaging and diagnostics in motion, MIDOM. Collaborator, (2014-2016)
MZOS RH: Genotoxicity of physical and chemical agents of natural and anthropogenic origin. Collaborator (2007-2014)
HRZZ: New protein networks for new therapeutic pathways in human melanoma. Collaborator (2014-2016)
Adris Foundation: BIOBREAST - New markers for breast tumor detection and monitoring. Collaborator (2017-2019).
University Hospital, Basel, Switzerland: Customized axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). Multicenter randomized phase III trial. Principal investigator at KBCSM (2018-)
